<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02891447</url>
  </required_header>
  <id_info>
    <org_study_id>2016-0269</org_study_id>
    <secondary_id>NCI-2018-02341</secondary_id>
    <secondary_id>2016-0269</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT02891447</nct_id>
  </id_info>
  <brief_title>Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer</brief_title>
  <official_title>A Phase II Study of Cytoreduction, Gastrectomy, and Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well heated mitomycin and cisplatin during surgery work in
      treating patients with stomach or gastroesophageal cancer. Drugs used in chemotherapy, such
      as mitomycin and cisplatin, work in different ways to stop the growth of tumor cells, either
      by killing the cells, by stopping them from dividing, or by stopping them from spreading.
      Heating a chemotherapy solution and infusing it directly into the abdomen may kill more tumor
      cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess overall survival from the date of diagnosis in subjects with stage IV gastric or
      gastroesophageal cancer and positive cytology or carcinomatosis after cytoreduction,
      gastrectomy, and hyperthermic intraperitoneal chemotherapy administration.

      SECONDARY OBJECTIVES:

      I. To assess the safety of cytoreduction, gastrectomy, and hyperthermic intraperitoneal
      chemotherapy administration for subjects with gastric or gastroesophageal cancer and positive
      cytology or carcinomatosis.

      OUTLINE:

      Patients undergo hyperthermic intraperitoneal chemotherapy (HIPEC) comprised of mitomycin and
      cisplatin given intraperitoneally over 60 minutes during standard of care cytoreduction and
      gastrectomy.

      After completion of study treatment, patients are followed up within 4 weeks, and then every
      6 months for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 1, 2016</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the time of diagnosis of stage IV disease up to 5 years</time_frame>
    <description>Overall survival time will be estimated using the Kaplan-Meier method. The two-sided log-rank test will be used to assess the differences of time to events between groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patterns of tumor recurrence</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be assessed by reviewing routine surveillance imaging.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the time of surgery up to 5 years</time_frame>
    <description>Overall survival time will be estimated using the Kaplan-Meier method. The two-sided log-rank test will be used to assess the differences of time to events between groups.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Gastric Adenocarcinoma</condition>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Peritoneal Carcinomatosis</condition>
  <arm_group>
    <arm_group_label>Treatment (mitomycin, cisplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo HIPEC comprised of mitomycin and cisplatin given intraperitoneally over 60 minutes during standard of care cytoreduction and gastrectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given intraperitoneally</description>
    <arm_group_label>Treatment (mitomycin, cisplatin)</arm_group_label>
    <other_name>Abiplatin</other_name>
    <other_name>Blastolem</other_name>
    <other_name>Briplatin</other_name>
    <other_name>CDDP</other_name>
    <other_name>Cis-diammine-dichloroplatinum</other_name>
    <other_name>Cis-diamminedichloridoplatinum</other_name>
    <other_name>Cis-diamminedichloro Platinum (II)</other_name>
    <other_name>Cis-diamminedichloroplatinum</other_name>
    <other_name>Cis-dichloroammine Platinum (II)</other_name>
    <other_name>Cis-platinous Diamine Dichloride</other_name>
    <other_name>Cis-platinum</other_name>
    <other_name>Cis-platinum II</other_name>
    <other_name>Cis-platinum II Diamine Dichloride</other_name>
    <other_name>Cismaplat</other_name>
    <other_name>Cisplatina</other_name>
    <other_name>Cisplatinum</other_name>
    <other_name>Cisplatyl</other_name>
    <other_name>Citoplatino</other_name>
    <other_name>Citosin</other_name>
    <other_name>Cysplatyna</other_name>
    <other_name>DDP</other_name>
    <other_name>Lederplatin</other_name>
    <other_name>Metaplatin</other_name>
    <other_name>Neoplatin</other_name>
    <other_name>Peyrone's Chloride</other_name>
    <other_name>Peyrone's Salt</other_name>
    <other_name>Placis</other_name>
    <other_name>Plastistil</other_name>
    <other_name>Platamine</other_name>
    <other_name>Platiblastin</other_name>
    <other_name>Platiblastin-S</other_name>
    <other_name>Platinex</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol- AQ</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>Platinol-AQ VHA Plus</other_name>
    <other_name>Platinoxan</other_name>
    <other_name>Platinum</other_name>
    <other_name>Platinum Diamminodichloride</other_name>
    <other_name>Platiran</other_name>
    <other_name>Platistin</other_name>
    <other_name>Platosin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperthermic Intraperitoneal Chemotherapy</intervention_name>
    <description>Undergo HIPEC</description>
    <arm_group_label>Treatment (mitomycin, cisplatin)</arm_group_label>
    <other_name>HIPEC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin</intervention_name>
    <description>Given intraperitoneally</description>
    <arm_group_label>Treatment (mitomycin, cisplatin)</arm_group_label>
    <other_name>Ametycine</other_name>
    <other_name>MITO</other_name>
    <other_name>MITO-C</other_name>
    <other_name>Mito-Medac</other_name>
    <other_name>Mitocin</other_name>
    <other_name>Mitocin-C</other_name>
    <other_name>Mitolem</other_name>
    <other_name>Mitomycin C</other_name>
    <other_name>Mitomycin-C</other_name>
    <other_name>Mitomycin-X</other_name>
    <other_name>Mitomycine C</other_name>
    <other_name>Mitosol</other_name>
    <other_name>Mitozytrex</other_name>
    <other_name>Mutamycin</other_name>
    <other_name>Mutamycine</other_name>
    <other_name>NCI-C04706</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2

          -  Cytologic or histologic proof of adenocarcinoma of the stomach or gastroesophageal
             junction

          -  Leukocytes &gt;= 3,000/uL

          -  Absolute neutrophil count &gt;= 1,500/uL

          -  Platelets &gt;= 60,000/Ul

          -  Serum creatinine =&lt; 1.5 mg/dL

          -  Distant metastatic disease of peritoneum may be visualized on imaging:

               -  Positive peritoneal cytology

               -  Carcinomatosis on diagnostic laparoscopy or laparotomy

          -  Completion of preoperative systemic chemotherapy and preoperative laparoscopic HIPEC

        Exclusion Criteria:

          -  Distant metastatic disease not limited to peritoneum: Solid organ metastases (liver,
             central nervous system, lung)

          -  Infections such as pneumonia or wound infections that would preclude protocol therapy

          -  Women with a positive urine or serum pregnancy test are excluded from this study;
             women of childbearing potential (defined as those who have not undergone a
             hysterectomy or who have not been postmenopausal for at least 24 consecutive months)
             must agree to refrain from breast feeding and practice adequate contraception as
             specified in the informed consent. Adequate contraception consists of oral
             contraceptive, implantable contraceptives, injectable contraceptives, a double barrier
             method, or abstinence

          -  Subjects with unstable angina or New York Heart Association grade II or greater
             congestive heart failure

          -  Subjects deemed unable to comply with study and/or follow-up procedures

          -  Subjects with a known hypersensitivity to protocol systemic chemotherapy that was
             life-threatening, required hospitalization or prolongation of existing
             hospitalization, or resulted in persistent or significant disability or incapacity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian D Badgwell</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>September 1, 2016</study_first_submitted>
  <study_first_submitted_qc>September 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2016</study_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

